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Alginate coated chitosan nanoparticlesivery system that is composed of a chitosan core to which the hepatitis B surface
antigen (HBsAg) was adsorbed and subsequently coated with sodium alginate. In this present work, alginate
coated chitosan nanoparticles were evaluated as a subcutaneous adjuvant for HBsAg.
HBsAg loaded, alginate coated or uncoated chitosan nanoparticles, associated or not with CpGODN were
subcutaneously administered to mice and several immunological parameters were evaluated.
A high anti-HBsAg IgG titer (2271±120 mIU/ml), with the majority of antibodies being of Th2 type, was
observed within group I, vaccinated with HBsAg loaded onto coated nanoparticles. However, regarding
cellular immune response, no significant differences were observed for antigen-specific splenocyte
proliferation or for the secretion of IFN-γ and IL-4, when compared to the control group. The co-delivery
of antigen-loaded nanoparticles in the presence of the immunopotentiator, CpG ODN 1826, resulted in an
increase of anti-HBsAg IgG titers that was not statistically different from the first group; however, an increase
of the IgG2a/IgG1 ratio from 0.1 to 1.0 and an increase (pb0.01) of the IFN-γ production by the splenocytes
stimulated with the HBV antigen was observed.
The enhancement of the immune response observed with the antigen-loaded nanoparticles demonstrated
that chitosan is a promising platform for parenteral HBsAg delivery and, when co-administered with the CpG
ODN, resulted in a mixed Th1/Th2 type immune response.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Chitosan, a biodegradable and biocompatible polysaccharide with
immunological activity [1,2], which acts both as a bioadhesive [3] and as
efficient absorption enhancer [4], has also been regarded as a promising
polymer for the formulation of vaccine delivery systems, especially for
application to mucosal surfaces [5]. Recently, we have designed a
delivery system composed of a chitosan core to which the hepatitis B
surface antigen (HBsAg)wasadsorbed andwas then coatedwith sodium
alginate. This delivery systemwas recently evaluated formucosal routes
of immunization.
On the other hand, the evaluation of chitosan as an adjuvant for
parenteral vaccinationhas been less studied and, inmost cases, the results
of these vaccination studies were reported together with the results of
intranasal or oral vaccination studies, making the possible value ofStudies, Faculty of Pharmacy,
oimbra, Portugal. Tel.: +351
l rights reserved.chitosan as an adjuvant for parenteral routes less noticeable in the
scientific literature. Generally speaking, the development of safe novel
adjuvants is necessary not only for the more challenging environment of
themucosal surfaces, but also for parenteral vaccination, tomaximize the
efficacy of newor alreadyavailable vaccines. In the last few years this idea
became even more urgent since newer generations of antigens are
predominantly purified recombinant proteins, which are often poorly
immunogenic. Additionally, the new generation of adjuvants may also
allow vaccination strategies to be applied to novel areas, including
“therapeutic” vaccines designed to control allergies, auto-immune
diseases,malignancies, drugdependencies, neural diseases, or fertility [6].
Despite the efficacy of hepatitis B vaccines, immunization failuremay
occur and can sometimes be explained by several factors such as
improper storage or administration of the vaccines, advanced age of the
individual, chronic liver disease, and immunosuppression. Genetically
determined resistance appears to be another important factor causing a
non-responder rate of up to 10% [7,8]. Moreover, all the conventional
licensed hepatitis B vaccines in use contain alum as adjuvant. Although it
is a potent B cell stimulator, alum is less effective in inducing a Th1
responseby the intramuscular route [9]. The Th1 type immune responses,
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factor-α (TNF-α), and opsonizing antibodies such as the IgG2a isotype, as
well as strong cytotoxic T-lymphocyte (CTL) induction, are necessary for
the control of intracellular infections, such as viral infections [10–12]. In
contrast, the development of a strong Th2 response, which is character-
ized by the secretion of IL-4 and IL-5 cytokines and antibodies such as
IgG1 and IgE, is more useful in combating extracellular infections [12].
The viral clearance in acute, self-limited hepatitis B virus infection
correlates with increasing CTL and T-helper cell activities and the
occurrence of anti-HBs antibodies [13]. In contrast, patients suffering
from chronic hepatitis B have insufficient or absent immune responses
[9,13]. On the other hand, experimental data support the hypothesis
that the enhancement of HBV-specific immune reactions could have
some beneficial effects in the therapy of chronic hepatitis B [13].
Therefore, it has been suggested [9] that the administration of the
hepatitis B vaccine alone, or in combination with diverse cytokines,
should be evaluated in future studies for treatment of chronic
hepatitis B virus infection. The usefulness of this therapeutic
vaccination may be further improved if the vaccine was able to
induce a stronger Th1 immune response.
The differentiation of an antigen specific CD4 T-helper subset (Th1
or Th2) takes place at the time of priming, and the type of stimulated
CD4 subset will depend on a number of factors, including the cytokine
environment [10]. The adjuvant used can alter the cytokine environ-
ment at the site of the primary immune response [10]. Therefore, the
selection of an appropriate adjuvant is the first step toward the
successful induction of an appropriate immune response.
In the present study, the abovementioned alginate coated chitosan
nanoparticles were investigated for the first time as adjuvant for
subcutaneous vaccination with the recombinant hepatitis B surface
antigen. Moreover, this paper investigates the co-administration of
CpG ODN 1826, a potent adjuvant in mice that was shown to induce
Th1 type immune response in combinationwith a number of different
antigens, such as influenza virus [14], hepatitis B antigen [15–17], and
tetanus toxoid [18], with the nanoparticles.
2. Materials and methods
2.1. Materials
2.1.1. Polymers
Chitosan was purchased from Primex BioChemicals AS (Avaldsnes,
Norway). According to the provider's specifications, the degree of
deacetylation was 95% (titration method) and the viscosity 8 cP
(measured in 1% solutions in 1% acetic acid). A low molecular weight
pharmaceutical grade sodium alginate (MANUCOL LB®) was kindly
donated by ISP Technologies Inc. (Surrey, UK). According to the
provider's specifications, the typical values for the percentage of
mannuronic and guluronic acid for Manucol LB were 61% and 39%,
respectively, with an estimated molecular weight of 18 kDa.
2.1.2. Antigen, adjuvant and reagents
The hepatitis B surface antigen (HBsAg), (subtype ADW2) was
kindly provided by GSK Biologicals (Rixensart, Belgium), Class B, CpG
ODN (1826) (5′-TCC ATG ACG TTC CTG ACG TT-3′) was purchased from
Coley Pharmaceutical Group (Ottawa, Canada).
Concanavalin A (Con A), phenylmethanesulfonyl fluoride (PMSF),
avidin peroxidase conjugate and the BCIP/NBT-purple liquid substrate
system for membranes were purchased from Sigma Chemicals (St. Louis,
USA). Certified foetal bovine serum (FBS) and L-glutamine (200mM)were
fromGibco (Invitrogen Co, Paisley, Scotland, UK),1MHEPES buffer (0.85%
NaCl), RPMI 1640without L-glutamine and Pen-Strep (10,000Upenicillin/
ml; 10,000 μg streptomycin/ml) were from Biowhitaker (Cambrex Bio
Science, Verviers, Belgium). [methyl-3H] thymidine (1.0 mCi/ml) was
obtained from Amersham Biosciences (UK) and R-phycoerythrin (PE)-
conjugated hamster anti-mouse CD69, fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse CD4 and FITC-conjugated rat anti-mouse CD8
were obtained from BD Biosciences (Madrid, Spain). The FITC-conjugated
goat anti-mouse IgM (anti-µ), the anti-mouse IFN-γ and biotin rat anti-
mouse IFN-γwas purchased from PharMingen (San Diego, CA, USA). The
mouse IgA ELISAquantification kitwas obtained fromBethyl Laboratories,
(Montgomery, USA). All other reagents used were of analytical grade. All
solutions were prepared in ultrapure water.
2.2. Methods
2.2.1. Preparation of the coated nanoparticles
The preparation of the alginate coated chitosan nanoparticles was
performed according to themethod previously described [19]. In brief,
chitosan was dissolved at a concentration of 0.25% (w/v) in diluted
acetic acid solution. The formation of the particles was achieved by the
addition of 3.5 ml of sodium sulphate solution (10% w/v) to 200 ml of
the chitosan solution. The resulting suspension was centrifuged for
30 min at 3500 rpm (2800×g) and the supernatant was discarded. The
particles were re-suspended in Millipore water and centrifuged twice.
They were finally frozen in liquid nitrogen and freeze-dried overnight
using a Labconco freeze dry system (Labconco Corporation, Kansas,
USA). The dry powder was kept frozen until further use.
The loading of the chitosan nanoparticles with HBsAg was
performed by incubating a solution of HBsAg with a suspension of
chitosan particles in phosphate buffer of pH 7.4 undermild agitation at
room temperature for 120 min. The resulting suspension composed of
0.015% (w/v) HBsAg and 0.5% (w/v) nanoparticles was used in the
subsequent coating step. Alginate coated nanoparticles were obtained
by mixing equal volumes of the HBsAg loaded nanoparticle suspen-
sion and a solution of sodium alginate in phosphate buffer (1% w/v)
under magnetic stirring. The agitationwas maintained for 20 min. The
suspension was then centrifuged for 10 min at 1600 rpm and the
supernatant was discarded. The particles were re-suspended in
0.262 mM CaCl2 in 50 mMHEPES buffer solution, kept under agitation
for another 10 min, and immediately administered to mice group I.
Group II received the same 1% particle suspension to which CpG ODN
had previously been added. Finally, a 1% chitosan nanoparticle
suspension, which contained CpG and the antigen, but was not coated
with alginate, was administered to mouse group III.
2.2.2. Evaluation of the loading efficacy of HBsAg and CpG ODN in coated
and uncoated nanoparticles
The loading efficacy of the coated and uncoated nanoparticles was
calculated indirectly by quantifying the antigen or the CpG ODN that
remained in solution as previously described [20,21].
The loading efficacy (LE) and the loading capacity (LC) were
calculated from the following equations:
LE kð Þ ¼ Total amount of HBsAg−free HBsAgð Þ
=Total amount of HBsAg⁎100
ð1Þ
LC μg of HBsAg=mg nanoparticles dry weightð Þ
¼ Total amount of HBsAg−free HBsAgð Þ
=mg chitosan nanoparticles dry weight:
ð2Þ
2.2.3. Immunization studies
2.2.3.1. Animals. Seven week-old female BALB/cAnNHsd mice were
used (Harlan Iberica, Barcelona, Spain) with four mice per group.
Animals were housed for acclimatization one week before the
experiments at the animal resource facilities of the Faculty. Animal
care, handling, and immunization protocols were adhered to the
“Principles of Laboratory Animal Care” and in accordance with
institutional ethical guidelines. The mice had free access to food and
water and were kept under a 12 h light/dark cycle.
Table 1
Resume of the formulations s.c. administered to mice groups
Group I Group II Group III Group IV
Chitosan nanoparticles (NP) X X X
Alginate coating X X
10 μg HBsAg loaded on NP X X X
10 μg HBsAg in PBS solution X
20 μg CpGODN loaded on NP X
20 μg CpG ODN in solution X
Each mouse received a volume of 100 μg of the formulation.
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alginate coated chitosan nanoparticles loaded with 10 μg HBsAg.
Group II- suspension of alginate coated chitosan nanoparticles
loaded with 10 μg HBsAg plus 20 μg of CpG ODN in solution.
Group III- suspension of the chitosan nanoparticles loaded with
10 μg HBsAg and 20 μg CpG ODN.
Group IV- Phosphate buffer saline (PBS; pH 7.4) solutionwith 10 μg
HBsAg (reference group).
Group V- untreated or control.
2.2.3.3. Immunization schedule. The primary immunization was
followed by one boost with three weeks between immunizations.
The mice were sacrificed four weeks after the boost. To evoke an
immune response, a total volume of 100 μl of the formulations was
subcutaneously administered to non-anesthetized mice.
2.2.3.4. Collection of samples. Blood samples were taken from the
orbital sinus before the boost and by cardiac puncture at the end of the
experiment. The sera were prepared by centrifugation and stored at
−20 °C until analysis.
Faecal pellets (4–8) were collected in Eppendorf tubes four and one
days before the end of the experiment. The pellets (0.2 g/ml) were
suspended in PBS (containing 0.1% sodium azide, 0.1% BSA, and 1 mM
PMSF), vortexed, and allowed to rest at room temperature for 1 h. Solid
matter was separated by centrifugation at 14,000 rpm for 15 min. The
clear supernatantswere frozen at −80 °Cuntil determinationof antigen-
specific and total secretory IgA by ELISA.
2.2.3.5. Enzyme-linked immunosorbent assays (ELISA) for HBsAg specific
immunoglobulins. Ninety-six-well flat-bottomed microtiter plates
(Nunc immunoplate maxisorb) were previously coated with recombi-
nant HBsAg (1 μg/well) dissolved in coating buffer (50 mM sodium
carbonate, pH 9.6) by overnight incubation at 4 °C. The plates were
washed five times with PBS-T (PBS containing 0.05% Tween-20) and
blocked with 3% BSA in PBS-T (200 μl/well) for 1 h at 37 °C. The plates
were then washed five times with PBS-T and the serial dilutions of
each serum (100 μl/well) from the individual mice were tested in
triplicate, starting from a 1:100 dilution in PBS-T. The serum was
incubated for 2 h at 37 °C and after washing the plates with PBS-T, the
plates were incubated for additional 30 min at 37 °C with peroxidase-
labelled goat anti-mouse immunoglobulin G and isotypes (anti-IgG1,
anti-IgG2a, anti-IgG2b, and anti-IgG3). The bound antibodies were
revealed by adding 100 μl/well of 0.5 mg/ml of o-phenylenediamine
dihydrochloride (OPD) (Sigma, Spain) in 10 ml of citrate buffer with
10 μl of H2O2. The reaction was stopped after 10 min with 50 μl of 3 M
HCl to each well. The absorbance was read at 492 nm in an automatic
ELISA reader (Easy Reader 400, SLT-LABINSTRUMENTS). ELISA titers
were expressed as mIU/ml, and 1 mIU is the mean OD of the pre-
immune serum plus two times the standard deviation.
The measurement of IgA was carried out using a mouse IgA ELISA
quantification kit (Bethyl Laboratories, Montgomery, Texas, USA) as
described by the manufacturer. In order to measure the sIgA levels in
the faeces, total sIgA and the specific anti-HBs sIgA were determined
in the extracts. The results are presented as the anti-HBsAg IgA/totalIgA. By this way, variations between samples related with the
extraction process or stability of the sIgA were minimized.
The IgA standard was diluted to appropriate concentrations in PBS
with 1% BSA to create a calibration curve. The gut washes were diluted
in PBS-T with 1% BSA and added to the plates in series of two-fold
dilutions. The concentrations of the total and specific IgA were
determined from the calibration curve generated for each set of
samples using a four parameter logistic curve-fit generated by
SigmaPlot software (version 8.0, SPSS Inc).
2.2.3.6. Preparation of spleen cell suspensions. The mice were
euthanized by cervical dislocation and their spleens were aseptically
removed. Individual spleen cell suspensions were prepared in a Petri
dish using curved needles and washed twice with RPMI 1640. The
final suspension was adjusted to a final concentration of 1×107 cells/
ml in complete RPMI 1640 medium supplemented with 10% (v/v)
foetal bovine serum (FBS), 1% (v/v) glutamine, 1% (v/v) Pen-Strep, and
2% (v/v) 1 M HEPES buffer.
2.2.3.7. Splenocyte cell culture in the presence of the mitogens. Using
sterile 96-well flat-bottomed tissue culture plates, 25 μl of splenocyte
suspension (1×107 cells/ ml) from each mouse were plated in triplicate
with25 μl of concentratedRPMI solutionof themitogen [ConA (50 μg/ml),
CpG ODN (50 μg/ml) plus HBsAg (16 μg/ml), HBsAg (16 μg/ml) alone, or
withoutmitogen (control)]. Finally, the volume of thewellwasfilled up to
200 μl with complete RPMI and incubated according to the following
conditions (see Sections 2.2.3.8 and 2.2.3.9).
2.2.3.8. Cytokine production by splenocytes. Spleen cell suspensions
were plated with the appropriate mitogen (see Section 2.2.3.7) and
incubated in a humidified 5% CO2 incubator for 48 h (IL-4, IL-10) and
96 h (IFN-γ) at 37 °C. The plates were centrifuged and the clear
supernatants stored at −80 °C until analysis of the cytokines by ELISA
technique described elsewhere [22].
2.2.3.9. Lymphoproliferation assay. Splenocytes were obtained and
cultured together with the mitogens in flat-bottomed 96-well plates as
described before (see Section 2.2.3.7). The cells were cultured for 96 h at
37 °C and during the last 8 h of incubation, each well was pulsed with
1 µCi of [methyl-3H] thymidine. The 96 well plates with the cells were
stored at −20 °C until further analysis. The cells were later thawed and
harvested onto a fiberglass filter (filtermats,molecular devices, Skatron,
Lier, Norway) using a semiautomatic cell harvester (Scatron Instru-
ments, USA) andDNA thymidine incorporationwas counted by standard
liquid scintillation techniques with a Beckman LS 6500 scintillation
counter (BeckmanCoulter Inc., Fullerton,USA). Thymidine incorporation
was expressed as counts per minute (cpm).
2.3. Statistical analysis
If another method is not explicitly stated, the data are presented as
the mean±S.E.M. for at least three experiments and statistical
significance was assessed using one-way analysis of variance (ANOVA)
followed by Dunnett's post test for comparing the vaccinated groups
with the control group. The Kruskal–Wallis test, followed by Dunn's
multiple comparison test, were used for comparing the cytokine values
between the groups using the Prism 4 (GraphPad software, CA, USA).
Differences were considered significant when pb0.05.
3. Results
3.1. Characterization of the alginate coated chitosan nanoparticles
Our group recently reported on the development of alginate coated
chitosan nanoparticles and the characterization of this new delivery
system [19]. Briefly, before coating with sodium alginate, chitosan
Fig. 1. Total number of splenocytes from groups (I, II, III, IV and V). Each bar corresponds
to the group geometric mean plus the standard error of the mean. (⁎pb0.05; t-test).
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coating with alginate they became negatively charged (−34.9 mV±
8.3). Chitosan nanoparticles had a mean diameter of 643±171.7 nm
measured by dynamic light scattering technique. More recently [20],
we published the results of ovalbumin (model vaccine) release studies
from coated and uncoated nanoparticles. Ovalbumin release studies,
performed in several buffers at different pH values, allowed us to
conclude that the coating of the ovalbumin loaded chitosan
nanoparticles prevented an ovalbumin burst release which was
observed with the uncoated chitosan nanoparticles at pH 5.5; 6.8,
and 7.4 (phosphate buffer) within the first 30 min of incubation.
3.2. Hepatitis B antigen and CpG adsorption to nanoparticles
Hepatitis B antigen was efficiently associated with alginate coated
chitosan nanoparticles. The loading efficacy of hepatitis B vaccine in
the coated nanoparticles was 77.1±3.0% (mean±STDEV) and the mean
of the loading capacity was 23.1 μg of HBsAg/mg of dry chitosan
nanoparticles±2.1 (STDEV). The adsorption efficacy of CpG to the
chitosan nanoparticles was 97.0±1.3% and the loading capacity was
29.0±0.03 (μg of CpG ODN/mg of dry chitosan nanoparticles).
3.3. Cellular immune response to subcutaneous administration of HBsAg
associated with the chitosan nanoparticles
The total numberof splenocyteswasevaluatedonweek fourafter the
boost and the results are shown in Fig. 1. At this time point the group II
showed a higher number of cells in the spleen when compared with
control group (Group V). Additionally, possible differences in the
maturation state of the splenocytes were also studied. Two of the
parameters observed were their ability to proliferate (Fig. 2) and to
produce cytokines (Fig. 3) after in vitro stimulationwith HBsAg, HBsAg+
CpGODN, and Con A (positive control). As expected, after 96 h of culture
without any external stimulation (Fig. 2A), the splenocytes did not
exhibit significant proliferative activity. Group IVwas an exception,with
a mean value statistically higher (pb0.05) than the control group;
however with a high variability within the group (Fig. 2A). The same
behaviour was observed when the splenocytes from the same group IV
were in vitro stimulated with the antigen (Fig. 2B) or with the antigen +
CpG ODN (Fig. 2C), but not with Con A (Fig. 2D). A Similar cellularFig. 2. Lymphoproliferative response after sc administration of the different hepatitis B
vaccine formulations. In vitro proliferation of individual mouse splenocytes for a 96 h
period stimulated with: A)—without stimulus. B)—HBsAg. C)—HBsAg + CpG ODN. D)—
Con A. Each circle represents the result of individual samples and the horizontal bar the
mean of the group. The results corresponded to the thymidine incorporation and are
expressed as counts per minute (cpm).immune response was observed within the group II, where a higher
proliferative responsewas selective to the presence of the antigen alone
(pb0.01) (Fig. 2B) or the antigen plus the CpG ODN (pb0.05) (Fig. 2C).
Fig. 3. Cytokine production by splenocytes. The spleens were harvested at 4 week post
boost and suspension of individual spleen cells were culturedwith either medium alone
or in the presence of different stimulus (HBsAg, Con A and HBsAg+CpGODN). Each bar
corresponds to the group geometric mean plus the standard error of the mean.
Comparisons weremade between treatment groups and control (group V). ⁎pb0.05 and
⁎⁎pb0.01. A)—Data are IL-10; B)—Data are IL-4; C)—Data are IFN-γ.
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IL-10, IL-4 and IFN-γ cytokines were also analysed in the culture
supernatants. It was not possible to detect IL-10 in the supernatants of
splenocytes cultured without mitogenic compounds or incubated in
the presence of the HBsAg (data not shown). On the other hand, in
vitro stimulationwith con A (positive control) or with antigen plus the
CpG ODN resulted in a production of IL-10 that was similar in almost
all the groups (Fig. 3A). To note that splenocytes from group IV,
stimulated with Con A seemed to be able to produce a significantly
higher amount of IL-10, however the increase found is only 1.6-foldwhen compared to the control group, therefore, probably of low
biological significance.
The profile of the cell-mediated immune response, specifically IFN-
γ (Th1) and IL-4 (Th2) cytokines, was also examined. Groups I and II
(vaccinated with the HBsAg associated with coated nanoparticles and
with coated nanoparticles + adjuvant, respectively) did not show any
modification of the production of IL-4, when compared to the control
group (data not shown). Conversely, at the same time point, mice from
groups III and IV showed low IL-4 levels (data not shown), in close
proximity to undetectable levels. On the other hand, following
splenocyte in vitro stimulation with a solution containing HBsAg +
CpG ODN, a small, but significant IL-4 enhancement was observed in
almost all the vaccinated groups (Fig. 3B). At the same time, lower
amounts of interferon-γ in the supernatants of the splenocytes
cultured for 96 h without any mitogen, compared to the non
vaccinated mice (control group), were observed in all vaccinated
groups (Fig. 3C). However, a different result was obtained when the
splenocytes were incubated with different mitogens. In the presence
of the HBsAg, only group IV showed a higher concentration (pb0.05)
of the interferon, but with a high standard deviation. With regard to
the in vitro stimulationwith HBsAg plus CpGODN, group III produced a
lower amount of the interferon (pb0.01). Also of note is the
comparison between the two groups vaccinated with formulations
containing the CpG ODN, groups II and III. In group III, a significant
(pb0.01) decrease in the concentration of the γ-IFN in the super-
natants of the cells in vitro stimulated with the antigen plus the
adjuvant was observed.
The ability of CpG ODN as adjuvant to induce Th1 type cytokines
has been previously demonstrated [10]. However, according to the
cytokine data obtained in this recent study, a clear Th1 cellular
immune response induced by CpG containing formulations was not
observed. At the same time, a Th1/Th2 mixed response was observed
in the group vaccinated with a saline solution of the antigen, which
has also been reported and attributed to the HBsAg itself [23].
3.4. Humoral immune response following subcutaneous administration
of HBsAg associated with nanoparticles
3.4.1. Systemic immune response
The association of the HBV antigen (group I) to the alginate coated
chitosan nanoparticles induced a strong immune response that was
5.3-fold higher than the mean titer found for group IV, vaccinated
with the antigen without any adjuvant (Fig. 4A). In group I, both anti-
HBsAg IgG1 and IgG2a were detected in the serum, however there
was a clear predominance of IgG1 (Fig. 4B). The addition of the CpG
ODN to the formulation used on the group I, which was given to group
II, resulted in an increase in anti-HBsAg IgG2a antibody titers and a
decrease of anti-HBsAg IgG1 antibody titers. Thus, the main impact
was the breaking of the clear predominance of the Th2 immune
response for the induction of a mixed Th2/Th1 response (Fig. 4C).
Moreover, the mean IgG titers were not different between the groups I
and II. Consequently, it can be concluded that the immune response
differences between the two groups are only qualitative. Finally,
group III was vaccinated with HBsAg + CpG ODN adsorbed to the
uncoated chitosan nanoparticles. A strong HBsAg specific IgG immune
response was observed and was 7.7-fold higher than the mean value
found for the control group. Moreover, in a comparison of group I
with group III, the values of the anti-HBsAg IgG were not significantly
different. However, similar to group I, group III showed a predomi-
nance of the IgG1 antibody subtype (Th2 profile immune response).
The amount of CpG ODN administered to both groups II and III was
equal. In group III, the CpG ODN was associated with the chitosan
nanoparticles and might was therefore less available to interact with
the immune cells. Therefore in group III, CpG seemed to exert a
smaller effect, resulting in the decreased ratio of IgG2a/IgG1 of 1.0 in
the group II to 0.7 in the group III (Fig. 4C). In fact, both groups (II and
Fig. 4. A)—Serum anti-HBsAg IgG titers of mice immunized with different formulations
of hepatitis B vaccine. Values are expressed as antibody titers of individual mice taken in
the end of the experiment. The horizontal bar is the mean of the group. t-test was used
for analysis of significance between each group and the group IV. B)—Serum anti-HBsAg
IgG1 and IgG2a titers (logarithmic scale) of mice immunized with different formula-
tions of hepatitis B vaccine. The bar corresponds tomean titer in each group. Titers were
defined as the highest plasma dilution resulting in an absorbance value twice that of
nonimmune plasma (1 mlU/ml=mean+2 SD of the control group). C)—Ratio IgG2a/
IgG1.
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different (t-test; pb0.05) between the same above groups, being
higher in group vaccinated with the formulation where the CpG was
associated with chitosan.
3.4.2. Mucosal immune response
In this study, the quantification of anti-HBsAg sIgA was performed
on extracts of fresh faeces, collected two days before the end of the
experiment. As expected, the subcutaneous administration of the
vaccine formulations was unable to induce the production anti-HBsAg
IgA (data not shown).4. Discussion
We recently described a new delivery system composed of a
chitosan core to which the antigen was adsorbed and which was
successively coated with sodium alginate. One advantage of this
delivery system is that the antigen is encapsulated under non-
stressful conditions, such that the biological properties of the antigen
are expected to remain intact. In this study, the potential of chitosan
nanoparticles as an adjuvant for the hepatitis B surface antigen
administered subcutaneously, was evaluated for the first time. The
adjuvant effect of the alginate coated chitosan nanoparticles (group I)
was clearly demonstrated by the production of high anti-HBsAg IgG
titers with a clear dominance of Th2 type antibodies (IgG1N IgG2a). A
similar behaviour (IgG1N IgG2a) was recently reported with a
different type of nanoparticles and antigens, like tetanus toxoid-
loaded poly(D, L-lactic-co-glycolic acid) nanoparticles [18] or with
liposome-encapsulated influenza subunits [24], both administered
subcutaneously. Alginate coated chitosan nanoparticles stimulated
both Th1 and Th2 type antibodies, however, IgG2a antibodies were
induced at a lower percentage, resulting in a decrease of the IgG2a/
IgG1 ratio from 0.4 (control group) to 0.1. It can be considered that the
Th2 immune profile was enhanced, when the alginate coated chitosan
nanoparticles were used as an adjuvant. A similar observation was
recently reported by us with the same mice strain [25] and after
intranasal administration of the antigen associated with alginate
coated nanoparticles. Moreover, the same previous study also
revealed that the induction of a Th2 immune response is also a
characteristic of the hepatitis B commercial formulation (adjuvanted
with alum). Likewise, the enhancement of the Th2 profile immune
response, after intranasal immunization with a formulation contain-
ing chitosan nanoparticles associated to genetically detoxified
diphtheria toxin, was reported by others, as well [26].
Analysing the cellular immune responses, it was possible to
observe a higher proliferation capability of the spleen cells, stimulated
in vitrowith Con A, from group vaccinated with HBsAg associated with
coated nanoparticles. However, an up-regulation of Th2 type
cytokines (i.e., IL-4) produced by the same splenocytes was not
observed. Furthermore, a down-regulation of IFN-γmay indicate that
natural killer T (NKT) and T cells (Th1 type cells), which are both IFN-γ
producers [13], were less activated in comparison with the same cells
from the unvaccinated mouse group.
It has been demonstrated that a cell-mediated immune response,
particularly a Th1 response, is important not only for preventing, but
also for overcoming HBV infections [13,27] and eliminating the virus
from the infected cells [12]. At the same time, it has been suggested
that the conventional vaccine is able to elicit a high humoral immune
response, but failed to elicit a cell-mediated immune response,
rendering it ineffective for the treatment of chronic hepatitis B
infection [28]. Therefore, the study of new potential adjuvants with
emphasis on their capacity to induce a cell-mediated immune
response has been, in the last years, reported in the literature [28–
30]. In the present study CpG ODN 1826 was included in the
formulation (group II) to enhance the level of response or to focus
the response through a Th1 pathway [10,16,17,31]. In fact an increase in
the anti-HBsAg specific IgG2a antibodies and a slight decrease in IgG1
titers were observed in group II, but the total titer of HBsAg specific IgG
antibodies was not significantly different from the previous group
(Group I). Therefore, in this study, the ability of the CpG ODN to induce
a Th1 profile immune responsewas confirmed oncemore. On the other
hand, an additive effect with the nanoparticles was not observed,most
likely because chitosan nanoparticles seemed to be already a strong
adjuvant. A similar profile of humoral immune response was recently
described with tetanus toxoid-loaded PLGA microspheres and CpG
ODN in solution [18]. In contrast, on the same cited study the inclusion
of CpG ODN in nanoparticles with tetanus toxoid resulted in the
enhancement of interferon production in all cases.
1779O. Borges et al. / International Immunopharmacology 8 (2008) 1773–1780Coated chitosan nanoparticles were originally designed for
transporting recombinant protein antigens through mucosal surfaces
where the presence of proteolytic enzymes or the acid environment of
the stomach might destroy the antigen previously adsorbed to the
surface of the particles. The coating with alginate of the chitosan
nanoparticles might not be necessary when the delivery system is
going to be administered by the subcutaneous route. So, in order to
test this hypothesis a more simple formulation was studied. In this
case, the effect of the co-adsorption of the antigen and the CpG ODN
on chitosan nanoparticles was tested, avoiding the coating procedure
with sodium alginate. Furthermore, a second advantage of this
delivery system is related with its ability to present multiple copies
of the antigen on the surface, an effect which has been shown to be
optimal for B cell activation [32]. Moreover, the co-adsorption of the
antigen and the CpG ODN to the same nanoparticles has been
designated as the ideal formulation [33–36]. The s.c. vaccination with
this formulation resulted in the highest specific IgG titre and a mixed
Th1/Th2 immune response [24]. Interestingly, comparing the IgG2a/
IgG1 ratio of this group with the previous one (group II), where the
CpGwas not associated with the nanoparticles, a lower increase of the
IgG2a was observed. All the observations seemed to support the idea
that the free CpG ODN (not associated with the chitosan nanoparti-
cles) was more efficacious, presumably because it was more accessible
to interact with immune cells. By contrast, other studies on particulate
delivery of CpG, either surface adsorbed [37], in liposomes [34], or in
PLGA nanoparticles [18], found a stronger effect when CpG ODN was
encapsulated in the delivery system in comparison with CpG ODN in
solution. This feature was considered important since it would allow
for a decrease in dosage of CpG ODN administered while obtaining the
same effect. Two different mechanisms can be discussed to explain
our results. The first is related to the frequently reported strong
affinity between the CpG ODN and the cationic chitosan polymer
[38,39], which may cause a slow release of the CpG in vivo. Therefore,
the amount of free CpG ready to be internalized by the target cells is
lower when compared to the situation where the CpG ODN was given
in solution. The second putative mechanism is that the internalization
of the CpGODN into the cells is a prerequisite before it can bind toToll-
like receptor 9 (TLR9) present within a number of mouse immune cells
and subsequently trigger the immune response [36,40]. As supported
by theory and also by some experimental evidence [41], the
internalization of the CpG ODN would be facilitated if it was
administered in association with chitosan nanoparticles. However,
aggregation of the nanoparticles might occur in vivo compromising
the internalisation of the nanoparticles. This hypothesis cannot be
totally excluded and will be evaluated in future studies. Finally, even
under the assumption that chitosan nanoparticles have been inter-
nalized to some extent, the release of the CpG ODN from the particles
after their intracellular uptake should also be considered an important
issue which influences the efficacy of a vaccine formulation.
Another important advantage of the association of the CpG with
the nanoparticles is related with the protective effect against
enzymatic degradation of the CpG ODN. This aspect is particularly
important in the enzyme rich intestinal mucosa as previously reported
[41–43]. So, due to their unique and interesting properties, which have
been reviewed recently in several papers [3,44–47], chitosan and
chitosan nanoparticles have been used in mucosal delivery systems
for vaccination using several antigens and mucosal routes [26,48–51].
However, their potential as adjuvants for parenteral vaccination has
been less studied. In a very recent study [52], a chitosan solution was
explored as an adjuvant for subcutaneous vaccination of mice with a
model antigen. It was found that chitosan enhanced the antigen-
specific antibody titers over five-fold and antigen-specific CD4+
lymphocytes proliferation over six-fold. Mechanistic studies per-
formed by the same authors revealed that the antigen depot and a
transient cellular expansion in draining lymph nodes induced by
chitosan may explain its adjuvant properties [52].5. Conclusion
For the first time, the adjuvant effect of alginate coated chitosan
nanoparticles for the hepatitis B surface antigen was evaluated after
subcutaneous application in mice. A potent enhancement of the
humoral immune response was observed with predominance of Th2
type antibodies. The Th profile immune response was re-directed to
Th1 type when the antigen-loaded chitosan nanoparticles were co-
delivered with the CpG ODN 1826 in solution. A third formulation, in
which the antigen and the adjuvant were both adsorbed to chitosan
nanoparticles was also evaluated. No additional important benefits
were observed with this formulation. However, the manufacturing
simplicity of this last formulation makes it a potential basis for
future formulation improvements. All chitosan-based formulations,
containing CpGODN have shown a great potential for the improve-
ment of the currently licensed HBV vaccines, particularly making
them useful for the treatment of chronic hepatitis B, where Th-1
cellular immune response induction is required. Further dose–
response studies are required in order to evaluate and compare with
the existing vaccines in the market and with other adjuvants in
clinical investigation.
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